Genscript Biotech Management

Management Kriterienprüfungen 2/4

Genscript Biotech's CEO ist Weihui Shao, ernannt in Jul 2021, hat eine Amtszeit von 2.83 Jahren. besitzt direkt 0.021% der Aktien des Unternehmens, im Wert von HK$4.68M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.5 Jahre bzw. 7.1 Jahre.

Wichtige Informationen

Weihui Shao

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	2.9yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	3.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.2yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Weihui Shao (44 yo)

2.9yrs

Amtszeit

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 2.5m
Weihui Shao	CEO & COO	2.9yrs	keine Daten	0.021% $ 3.9m
Ye Wang	Co-Founder	22.4yrs	US$615.00k	0.037% $ 6.8m
Shiniu Wei	Chief Financial Officer	3.5yrs	keine Daten	keine Daten
Fangliang Zhang	co-founder & Executive Director	1.5yrs	US$271.00k	keine Daten
Li Zhu	Chief Strategy Officer & Executive Director	3.6yrs	US$529.00k	0.058% $ 10.8m
Wai Ling Wong	Company Secretary	8.8yrs	keine Daten	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: 1548Das Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 2.5m
Ye Wang	Co-Founder	9.1yrs	US$615.00k	0.037% $ 6.8m
Fangliang Zhang	co-founder & Executive Director	2.1yrs	US$271.00k	keine Daten
Li Zhu	Chief Strategy Officer & Executive Director	3.6yrs	US$529.00k	0.058% $ 10.8m
George Church	Member of Advisory Board	4.8yrs	keine Daten	keine Daten
Yuexin Pan	Non-Executive Director	8.8yrs	US$64.00k	0.0027% $ 495.7k
Hong Xin Guo	Independent Non-Executive Director	8.8yrs	US$95.00k	0.0029% $ 542.4k
Zumian Dai	Independent Non-Executive Director	8.8yrs	US$105.00k	keine Daten
Xuehai Wang	Independent Non-Executive Director	3.6yrs	US$120.00k	keine Daten
Luquan Wang	Non-Executive Director	9.1yrs	keine Daten	0.030% $ 5.6m
Jiuan Pan	Independent Non-Executive Director	5.6yrs	US$124.00k	keine Daten
Jiafen Wang	Non-Executive Director	5.6yrs	US$51.00k	0.00019% $ 35.5k

7.2yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 1548Die Vorstandsmitglieder gelten als erfahren (7.1 Jahre durchschnittliche Amtszeit).

Genscript Biotech Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Executive Chairman recently sold HK$610k worth of stock

Recent updates

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter